source
- Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trialGilead Sciences reported results from a Phase 2 trial of its oral ulcerative colitis drug emvistegrast. In the study, patients took a 200 mg daily dose for 12 weeks and achieved a 23% placebo-adju…
- Merck acquires Silence Therapeutics for $1.3B; Hansoh Pharma signs $15B deal with RocheGerman Merck announced the acquisition of Silence Therapeutics in a transaction valued at $1.3 billion. In China, Hansoh Pharma disclosed a partnership with Roche that involves a $15 billion drug…